

April 1, 2019

Bio:

Dr. William H. Tettelbach is a certified wound specialist who is actively board certified in Undersea & Hyperbaric Medicine, Infectious Diseases, Internal Medicine with formal training in Biomedical Informatics while retaining an academic appointment at Duke University School of Medicine. From 2000 to 2003 he served as Medical Director for TheraDoc, a provider of electronic clinical surveillance to healthcare organizations, and guided the development of their "Antibiotic Assistant," "Infection Control Assistant," and "Adverse Drug Event Assistant." These integrated clinical surveillance/decision support software modules have helped to enhance the quality and safety of patient care and are now utilized in over 2000 hospitals across the United States.

In 2003 Dr. Tettelbach became the acting Medical Director of Wound Care and Hyperbaric Medicine outpatient/inpatient services for the Methodist Le Bonheur Healthcare system. In 2004 he assumed the role Chief of Staff for Methodist Extended Care Hospital, a LTAC facility, as well as becoming an active member of the Methodist Extended Care Hospital Board of Directors. During his tenure in Memphis he was invited to participate in the response to The Surviving Sepsis Campaign, a global initiative to bring together professional organizations to reduce mortality from sepsis and, as a result, led the development of a Cerner rules-based electronic "sepsis alert" module. Since its successful development, the now labeled "St. John's Sepsis Surveillance Agent" to date has been implemented in over 550 hospitals in the United States and is currently being introduced into the United Kingdom.

In 2010, Dr. Tettelbach joined Intermountain Healthcare with the charge to lead the development of their wound care program. Undertakings included the establishment of a Hyperbaric and Wound Care Service Line as well as the introduction of a Hyperbaric Medicine Fellowship through a collaborative partnership with Duke University School of Medicine. Part of the restructuring involved introducing more level 1 evidence to the novel area of advanced wound healing therapies, especially to in the area of amniotic derived tissues. In 2012 Dr. Tettelbach became the national principle investigator over a 14 multicenter randomized controlled trial investigating the efficacy of dehydrated human amnion/chorion membrane (dHACM) allograft in the management of diabetic foot ulcers.¹ In 2014 Dr. Tettelbach was invited to become the Medical Director of

Infection Prevention, Antibiotic Stewardship & Wound Care at Landmark Hospital, Salt Lake City, UT. Infection prevention polices implemented at Landmark Hospital over the last five years have resulted in the lowest hospital acquired infection rates among LTACs in the State of Utah. Even with this new leadership responsibility, in 2016 Dr. Tettelbach again took on the role of national principle investigator over an 11 multicenter randomized controlled trial investigating the efficacy of dehydrated human umbilical cord (EpiCord) allograft in the treatment of diabetic foot ulcers.² Other past endeavors include coauthoring “A clinical practice guideline for the use of hyperbaric oxygen therapy in the treatment of diabetic foot ulcers.”³

The results of these amniotic tissue-based research projects have positively impacted wound care on a global stage by providing patients and clinicians with evidence-based wound healing solutions that safely and effectively close hard to heal wounds. He was also involved in a recently published chronic wound management consensus document in which TIME was expanded to TIMERS for the purpose of providing regenerative product and social impact recommendations regarding chronic wounds.⁴ Utilization of these now proven protocols have afforded countless patients suffering from chronic wounds to finally achieve wound closure, thus allowing patients to return to work, resume activities of daily living and improve their overall quality of life.

Dr. Tettelbach’s passion in medicine has been dedicated to not only improving patient outcomes, but he has strived to enhance healthcare delivery, reduce medical errors/costs and foremost bring needed guidance to the specialty of Advanced Wound Care and Hyperbaric Medicine. Dr. Tettelbach is currently the acting Associate Chief Medical Officer for MiMedx Group, Inc. in Marietta, GA. He is an active member of the Utah Medical Association Medicare Carrier Advisory Committee (CAC), and has been invited to assist in the revision of recent proposals presented to the Physician-Focused Payment Model Technical Advisory Committee (PTAC) which make recommendations to the Secretary of the Department of Health and Human Services (HHS) on proposals for physician-focused payment models (PFPMs). Dr. Tettelbach continues to treat Wound Care and Infectious Diseases patients as Medical Director of Wound Care, Antibiotic Stewardship and Infection Prevention at Landmark Hospital in Salt Lake City, UT.

References:

1. Tettelbach W, Cazzell S, Reyzelman AM, Sigal F, Caporusso JM, Agnew PS. A confirmatory study on the efficacy of dehydrated human amnion/chorion membrane dHACM allograft in the management of diabetic foot ulcers: A prospective, multicentre, randomised, controlled study of 110 patients from 14 wound clinics. *Int Wound J*. 2019 Feb;16(1):19-29. doi: 10.1111/iwj.12976. Epub 2018 Aug 22. PMID: 30136445
2. Tettelbach W, Cazzell S, Sigal F, Caporusso JM, Agnew PS, Hanft J, Dove C. A multicentre prospective randomised controlled comparative parallel study of dehydrated human umbilical cord (EpiCord) allograft for the treatment of diabetic foot ulcers. *Int Wound J*. 2019 Feb;16(1):122-130. doi: 10.1111/iwj.13001. Epub 2018 Sep 24. PMID: 30246926
3. Bianchi C, Tettelbach W, Istwan N, Hubbs B, Kot K, Harris S, Fetterolf D. Variations in Study Outcomes Relative to Intention-to-Treat and Per-Protocol Data Analysis Techniques in the Evaluation of Efficacy for Treatment of Venous Leg Ulcers with Dehydrated Human Amnion/Chorion Membrane Allograft. *Int Wound J*. 2019 Mar 12. doi: 10.1111/iwj.13094. [Epub ahead of print].
4. Atkin L, Bućko Z, Montero EC, Cutting K, Moffatt C, Probst A, Romanelli M, Schultz GS, Tettelbach W. Implementing TIMERS: the race against hard-to-heal wounds. *J Wound Care*. 2019 Mar 1;23(Sup3a):S1-S50. doi: 10.12968/jowc.2019.28.Sup3a.S1. No abstract available. PMID: 30835604.